PHIO - Phio Pharmaceuticals Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.25
+0.35 (+3.54%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.90
Open9.51
Bid10.10 x 800
Ask10.24 x 1000
Day's Range9.50 - 10.25
52 Week Range5.66 - 28.88
Volume41,692
Avg. Volume34,585
Market Cap6.862M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-20.10
Earnings DateAug 11, 2019 - Aug 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • PR Newswire

    Phio Pharmaceuticals Announces Reverse Stock Split

    Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-55. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 15, 2020 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 15, 2020 under the Company's existing trading symbol, "PHIO." At such time, the Company's common stock will also commence trading with a new CUSIP number, 71880W303.

  • PR Newswire

    Phio Pharmaceuticals to Present at Biotech Showcase 2020

    Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that its chief executive officer, Dr. Gerrit Dispersyn, will present at Biotech Showcase™ 2020 on Monday, January 13, 2020 at 2:00 pm Pacific Time at the Hilton San Francisco Union Square. Phio will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event being held at the Sir Francis Drake Hotel in San Francisco from January 13-15, 2020.

  • PR Newswire

    Phio Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders

    Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that its 2019 Special Meeting of Stockholders, scheduled for December 12, 2019, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved on the proposals to be approved. The Special Meeting will be reconvened at 9:00 a.m. (Eastern Time) at the Company's executive offices on January 10, 2020 to allow more opportunity for stockholders to vote on all proposals described in the Company's definitive proxy statement filed with the Securities and Exchange Commission (SEC) on November 22, 2019.

  • PR Newswire

    Phio Pharmaceuticals and Karolinska Institutet Expand Collaboration to Develop Self-Delivering RNAi Immunotherapies for Treating Solid Tumors

    MARLBOROUGH, Mass., Nov. 21, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next-generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that it expanded its research collaboration with the Karolinska Institutet in Stockholm, Sweden. The collaboration thus far has focused on the use of the Company's self-delivering RNAi compounds against targets involved in T cell and NK cell differentiation and/or tumor-induced stress response, with the aim of producing anti-tumor adoptive cell therapy grafts with improved functionality and persistence.

  • PR Newswire

    Phio Pharmaceuticals Announces Closing of Public Offering of Common Stock

    MARLBOROUGH, Mass., Nov. 20, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.10 per share. The gross proceeds from the offering, before deducting placement agent fees and other offering expenses, are approximately $1.0 million.

  • Benzinga

    The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • PR Newswire

    Phio Pharmaceuticals Announces Pricing of $1.0 Million Public Offering of Common Stock

    MARLBOROUGH, Mass., Nov. 18, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the pricing of its previously announced public offering of 10,000,000 shares of its common stock, at a public offering price per share of $0.10, for gross proceeds of $1.0 million, before deducting placement agent fees and other offering expenses. The offering is expected to close on or about November 19, 2019, subject to the satisfaction of customary closing conditions.

  • PR Newswire

    Phio Pharmaceuticals Announces Proposed Public Offering of Common Stock

    MARLBOROUGH, Mass., Nov. 13, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INSTASYL™) therapeutic platform, today announced that it has commenced a proposed public offering of shares of its common stock. All of the shares in the offering are to be sold by Phio. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Does Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Have A Particularly Volatile Share Price?
    Simply Wall St.

    Does Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Have A Particularly Volatile Share Price?

    If you're interested in Phio Pharmaceuticals Corp. (NASDAQ:PHIO), then you might want to consider its beta (a measure...

  • PHIO: Third Quarter 2019 Financial & Operational Update
    Zacks Small Cap Research

    PHIO: Third Quarter 2019 Financial & Operational Update

    By John Vandermosten, CFA NASDAQ:PHIO Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported third quarter 2019 results and filed its Form 10-Q on November 12, 2019. Since the beginning of the year, the company has announced a several new collaborations with partners including Glycostem Therapeutics, Helmholtz Zentrum Munchen and Carisma Therapeutics. Research and development efforts have put the

  • PR Newswire

    Phio Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    MARLBOROUGH, Mass. , Nov. 12, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...

  • PR Newswire

    Phio Pharmaceuticals to Highlight Self-delivering RNAi Technology at SITC 2019

    MARLBOROUGH, Mass. , Oct. 29, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...

  • PR Newswire

    Phio Pharmaceuticals Announces Adjournment of 2019 Annual Meeting of Stockholders

    MARLBOROUGH, Mass., Oct. 11, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that its 2019 Annual Meeting of Stockholders, scheduled for October 10, 2019, was convened and adjourned without any business being conducted due to the fact that a quorum was not achieved. The Annual Meeting will be reconvened at 9:00 a.m. (Eastern Time) at the Company's executive offices on October 24, 2019 to allow more opportunity for stockholders to vote on all proposals described in the Company's definitive proxy statement filed with the Securities and Exchange Commission (SEC) on August 30, 2019.

  • PR Newswire

    Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy

    MARLBOROUGH, Mass., Sept. 9, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it has entered into a research collaboration with Carisma Therapeutics to evaluate the potential of Phio's self-delivering RNAi compounds to synergistically modify Carisma's chimeric antigen receptor macrophages (CAR-M).  Silencing of key genes using sd-rxRNA compounds may enhance the immune function of these cells as a novel adoptive cell therapy for use in cancer treatment.

  • PR Newswire

    Phio Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Healthcare Conference

    MARLBOROUGH, Mass. , Sept. 3, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...

  • Zacks Small Cap Research

    PHIO: Overcoming Immune Checkpoints

    By John Vandermosten, CFA NASDAQ:PHIO READ THE FULL PHIO RESEARCH REPORT Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported second quarter 2019 results and filed its Form 10-Q on August 12, 2019. Since ...

  • PR Newswire

    Phio Pharmaceuticals and Helmholtz Zentrum München to Collaborate on Novel Targets for the Use of Self-Delivering RNAi In T Cell and NK Cell Adoptive Cell Therapy Therapeutics

    MARLBOROUGH, Mass. , Aug. 15, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...

  • PR Newswire

    Phio Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

    MARLBOROUGH, Mass. , Aug. 12, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...

  • Zacks Small Cap Research

    PHIO: Two Compounds Entering Clinic in 2020

    Since the beginning of the year, the company has announced a new collaborations with Glycostem Therapeutics, the promotion of Dr. Gerrit Dispersyn to CEO and the appointment of Dr. John Barrett as CDO. Phio’s lead candidate, RXI-762, is pursuing immuno-oncology indications in collaboration with Center for Cancer Immune Therapy (CCIT) and Iovance Biotherapeutics. Development efforts are centered on reducing the immune checkpoints that appear on the surface of tumor infiltrating lymphocytes (TILs) in an approach that can be layered on to current manufacturing processes.

  • PR Newswire

    Phio Pharmaceuticals to Present at Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum

    Will Also Attend 2019 ASCO Annual Meeting MARLBOROUGH, Mass. , May 20, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology ...

  • PR Newswire

    Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights

    - Expansion of Industry Partners With Glycostem Therapeutics BV Collaboration - Dr. John A. Barrett Appointed as Chief Development Officer - Reiterates Cash Expected to Provide Funding Into Second Half ...

  • Zacks Small Cap Research

    PHIO: Activation in the Tumor Microenvironment

    Phio Pharmaceuticals Corp. (PHIO) reported fourth quarter and full year results and filed its Form 10-K on March 27, 2018. Key operational events in 2018 include data presentations on NK cells, collaborations with Karolinska Institutet and Iovance Biotherapeutics and positive results from the Phase II assets. Other accomplishments include a change in the corporate name to Phio Pharmaceuticals, publication of sd-rxRNA immuno-oncology successes in Molecular Therapy and the elevation of Dr. Gerrit Dispersyn to Chief Executive Officer.

  • PR Newswire

    Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer

    MARLBOROUGH, Mass., April 10, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the appointment of Dr. John A. Barrett as the Company's Chief Development Officer effective as of April 22nd.

  • PR Newswire

    Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment

    MARLBOROUGH, Mass. , March 28, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that it has entered into a research collaboration with Glycostem Therapeutics BV to explore ...